0001005201-19-000131.txt : 20191202
0001005201-19-000131.hdr.sgml : 20191202
20191202172046
ACCESSION NUMBER: 0001005201-19-000131
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191201
FILED AS OF DATE: 20191202
DATE AS OF CHANGE: 20191202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peisert Daniel A.
CENTRAL INDEX KEY: 0001758376
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13111
FILM NUMBER: 191263961
MAIL ADDRESS:
STREET 1: C/O ASSERTIO THERAPEUTICS, INC.
STREET 2: 100 SOUTH SAUNDERS ROAD, SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Assertio Therapeutics, Inc
CENTRAL INDEX KEY: 0001005201
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943229046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
BUSINESS PHONE: (224) 419-7106
MAIL ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
FORMER COMPANY:
FORMER CONFORMED NAME: DEPOMED INC
DATE OF NAME CHANGE: 19970408
4
1
wf-form4_157532522943955.xml
FORM 4
X0306
4
2019-12-01
0
0001005201
Assertio Therapeutics, Inc
ASRT
0001758376
Peisert Daniel A.
ASSERTIO THERAPEUTICS, INC.
100 SOUTH SAUNDERS ROAD, SUITE 300
LAKE FOREST
IL
60045
0
1
0
0
SVP and CFO
Common Stock
2019-12-01
4
M
0
8359
0
A
83232
D
Common Stock
2019-12-01
4
F
0
2449
0.76
D
80783
D
Restricted Stock Units
2019-12-01
4
M
0
8359
0
D
2021-12-01
Common Stock
8359.0
16717
D
Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
One-third of these restricted stock units are scheduled to vest on each of December 1, 2019, 2020 and 2021.
The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
/s/ K.Amar Murugan, attorney in fact
2019-12-02